Immunophenotyping of Blast Cells and Immune Effector Cells in Peripheral Whole Blood and Bone Marrow Samples From AML and MDS Patients (AML)
Completed
- Conditions
- Leukemia
- Registration Number
- NCT03801005
- Lead Sponsor
- Assistance Publique Hopitaux De Marseille
- Brief Summary
The objective of this study is to evaluate the immune profile of blast cells and immune effector cells in paired peripheral whole blood and bone marrow samples from AML and MDS patients by standardized flow cytometry. A special emphasis will be focused on monitoring expression of CD200 as well as PGP-170 (MDR1) on blasts cells.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 38
Inclusion Criteria
- Age > 18
- No pregnant woman
- Patient with myelodysplastic syndrome (with excess blasts) or acute myeloid leukemia
- Presence of a monitored serum blastose
- Patient who can obtain free and informed consent (speaks French, no guardianship or curatorship)
Exclusion Criteria
- Minor Patient (< 18 years old)
- Medical or psychological Condition that could interact with the ability to understand the study,
- Pregnant or lactating women,
- Major persons under guardianship or under the protection of justice
- Persons deprived of their liberty by a judicial or administrative decision
- Lack of information and opposition to its participation in the study
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method evaluate the immune profile of blast cells and immune effector cells in paired peripheral whole blood and bone marrow samples from AML and MDS patients by standardized flow cytometry. 9 mounths
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Assistance Publique - Hopitaux de Marseille
🇫🇷Marseille, France